NEW YORK, Dec. 4 /PRNewswire/ -- PeriCor Therapeutics announced with sadness today the death of Ross Dixon, Ph.D., Vice President, Pharmaceutical Development.
"Ross became involved with the founders prior to the start-up of PeriCor and later joined us as the company's second employee," stated Richard R. Stover, President and CEO of PeriCor Therapeutics. "We relied heavily on Ross to spearhead and advance our pharmaceutical sciences and manufacturing effort. All of us at PeriCor admired Ross' tremendous technical skill as well as his enthusiasm in growing PeriCor to the next level." Stover added, "On behalf of the company, we extend our deepest sympathy to Ross' family and friends. He will certainly be missed."
Dr. Dixon joined PeriCor in March 2005 as Vice President, Pharmaceutical Development. He had more than 30 years of experience in the pharmaceutical and biotechnology industry. Prior to joining PeriCor, Dr. Dixon served as Executive Director, Drug Development of Ontogen Corporation, overseeing preclinical and clinical development of the Company's pipeline, having previously held senior drug development positions at Schering-Plough, Gensia and Hoffman-LaRoche. Dr. Dixon received his B.Sc. in Chemistry from Trinity College, Dublin and a Ph.D. in pharmacology from the University of Sheffield in the UK. He completed postdoctoral research at Columbia University.
About PeriCor Therapeutics
PeriCor Therapeutics, Inc. is a privately-held specialty biopharmaceutical company focused on the development and commercialization of a new class of medicines, adenosine regulating agents, to prevent the perioperative complications of surgery and improve the treatment and outcomes of acute cardiovascular care.
PeriCor Therapeutics, Inc.CONTACT: Richard R. Stover, PeriCor Therapeutics, Inc., +1-212-601-2725;or Roland Tomforde, Broadgate Consultants, +1-212-232-2356
